PTGX – protagonist therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
Form 4 Protagonist Therapeutics For: Feb 06 Filed by: Waddill William D.
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
Form 144 Protagonist Therapeutics Filed by: Waddill William D.
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: VANGUARD GROUP INC
Form 4 Protagonist Therapeutics For: Jan 23 Filed by: PATEL DINESH V PH D
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.